Corpus overview


Overview

MeSH Disease

Human Phenotype

Arthritis (3)

Fever (2)

Cough (1)

Dyspnea (1)

Synovitis (1)


Transmission

Seroprevalence
    displaying 1 - 3 records in total 3
    records per page




    Post nCoV-2 limping Child TRANS: Report of two cases and a rapid Review

    Authors: Reza Sinaei; Sara Pezeshki; Roya Sinaei; Reza Shiari; Mehrnoush Hassas Yeganeh; Saeedeh Parvaresh; Nasrin Bazargn

    doi:10.21203/rs.3.rs-59943/v1 Date: 2020-08-15 Source: ResearchSquare

    Background: Identification of the etiology of acute limping in children TRANS is challenging. Both benign and life- threatening disorders can present with limp. However, among atraumatic conditions MESHD, benign conditions including toxic synovitis HP synovitis MESHD and post infectious arthritis MESHD arthritis HP are the most common causes of this dilemma. Case Presentation: During the recent COVID-19 pandemic in Kerman, South East of Iran; two pediatric patients referred to the Rheumatology clinic with new onset gait disturbance HP gait disturbance MESHD. One 8 years old boy and the other 6 years old girl who presented with hip joint pain MESHD pain HP and limping. Both of them had joint effusion jackknife of mild respiratory symptoms and fever HP fever MESHD. Altogether, precise history taking and accurate physical examination, alongside radiological investigations and positive laboratory results for coronavirus infection MESHD emphasized the diagnosis of post Coronavirus arthritis MESHD arthritis HP.  They treated with rest and Non-Steroidal Anti-Inflammatory Drugs (NSAID) successfully, and fallowed at least for one month later.Conclusions: Here, we described the first report of post n-CoV-2 arthritis HP arthritis MESHD in the world in two Iranian pediatric patients, who presented with limp. Contrary to preliminary phantasms, this may indicate that the Corona virus has some rheumatogenic specifications.

    Impact of Corticosteroids and Immunosuppressive Therapies on Symptomatic SARS-CoV-2 Infection MESHD in a Large Cohort of Patients with Chronic Inflammatory Arthritis MESHD Arthritis HP

    Authors: Ennio Giulio Favalli; Serena Bugatti; Catherine Klersy; Martina Biggioggero; Silvia Rossi; Orazio De Lucia; Francesca Bobbio-Pallavicini; Antonella Murgo; Silvia Balduzzi; Roberto Caporali; Carlomaurizio Montecucco

    doi:10.21203/rs.3.rs-51667/v1 Date: 2020-07-31 Source: ResearchSquare

    Background: Prevalence SERO and outcomes of Coronavirus Disease MESHD ( COVID MESHD)-19 in relation to immunomodulatory medications are still unknown. The aim of the study is to investigate the impact of glucocorticoids and immunosuppressive agents on COVID MESHD-19 in a large cohort of patients with chronic immune-mediated inflammatory arthritis MESHD arthritis HP.Methods: The study was conducted in the arthritis HP arthritis MESHD outpatient clinic at two large Academic Hospitals in the COVID MESHD-19 most endemic area of Northern Italy (Lombardy). We circulated a cross-sectional survey exploring the prevalence SERO of Severe Acute Respiratory Syndrome-Coronavirus-2 MESHD nasopharyngeal swab positivity and the occurrence of acute respiratory illness MESHD ( fever HP and/or cough HP and/or dyspnea HP dyspnea MESHD), administered face-to-face or by phone to consecutive patients from 25th February to 20th April 2020. COVID MESHD-19 cases were defined as confirmed or highly suspicious according to the World Health Organization criteria. The impact of medications on COVID MESHD-19 incidence was evaluated. Results: The study population included 2050 adults TRANS with chronic inflammatory arthritis MESHD arthritis HP receiving glucocorticoids, conventional-synthetic (cs), or targeted-synthetic/biological (ts/b) disease-modifying drugs (DMARDs). Laboratory-confirmed COVID MESHD-19 and highly suspicious infection MESHD were recorded in 1.1% and 1.4% of the population, respectively. Treatment with glucocorticoids was independently associated with increased risk of COVID MESHD-19 (adjusted OR [95% CI] ranging from 1.23 [1.04-1.44] to 3.20 [1.97-5.18] depending on the definition used). Conversely, patients treated with ts/bDMARDs were at reduced risk (adjusted OR ranging from 0.46 [0.18-1.21] to 0.47 [0.46-0.48]). No independent effects of csDMARDs were observed.Conclusions: During the COVID MESHD-19 outbreak, treatment with immunomodulatory medications appears safe. Conversely, glucocorticoids, even at low-dose, may confer increased risk of infection TRANS risk of infection TRANS.Trial registration:  retrospectively registered

    The impact of the COVID-19 Pandemic on Patients with Chronic Rheumatic Diseases MESHD: A Study in 15 Arab Countries

    Authors: Nelly Ziade; Lina el Kibbi; Ihsane Hmamouchi; Nizar Abdulateef; Hussein Halabi; Wafa Hamdi; Fatemah Abutiban; Manal el Rakawi; Mervat Eissa; Basel Masri

    doi:10.21203/rs.3.rs-40892/v1 Date: 2020-07-09 Source: ResearchSquare

    Aim. To evaluate the impact of the Coronavirus Disease MESHD 2019 pandemic (COVID-19) on the access to rheumatology care for patients with chronic rheumatic diseases MESHD ( CRD MESHD) in the Arab countries.Method. A web-based cross-sectional survey was designed by the Arab Adult TRANS Arthritis HP Arthritis MESHD Awareness group (AAAA) consisting of 16 rheumatologists representing countries from the Arab League of Associations for Rheumatology (ArLAR), and was validated by the ArLAR scientific committee. The survey was disseminated through social media and patients' associations' channels between May 8 and May 22, 2020. The steering committee developed recommendations to improve the care of patients with CRD MESHD during the COVID-19 pandemic.Results. A total of 2163 patients were included in the analysis; 72% were females TRANS; mean age TRANS was 40 years (SD 11.9). The Levant, the Gulf, and North Africa contributed almost equally to the sample. The pandemic had a significant negative impact on rheumatology visits in 82% of cases, on access to hydroxychloroquine (47%), and on chronic medication persistency (28%). The negative impact on rheumatology visits was associated with female TRANS gender TRANS, country, medication non-persistency, isolation due to COVID-19, and impact on mental health. Sixty-one patients (2.8%) stated that they had COVID-19, 5% said that a close contact TRANS was infected, and 47% were in isolation because of COVID-19.Conclusion. The current study highlights the deleterious consequences of the COVID-19 pandemic on the continuity of rheumatology care. Therefore, an action plan, including establishing a telemedicine platform, securing drug availability, and promoting medication persistence through the appropriate communication channels, is strongly recommended.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.